Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease

Journal of Nephrology

Volumn 28, Issue 1, 2015, Pages 81-88

  Chand, Sourabh ^a,b   Ward, Douglas G ^a   Ng, Zhi Yan Valerie ^b   Hodson, James ^b   Kirby, Heidi ^b   Steele, Patricia ^b   Rooplal, Irina ^b   Bantugon, Ferly ^b   Iqbal, Tariq ^b   Tselepis, Chris ^a   Drayson, Mark T ^a   Whitelegg, Alison ^a   Chowrimootoo, Marie ^b   Borrows, Richard ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

CKD; Haemoglobin; Hepcidin; Iron; Prediction; Utility

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BILIRUBIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRIC CARBOXYMALTOSE; FERRITIN; FOLIC ACID; HEMOGLOBIN; HEPCIDIN; IRON; MYCOPHENOLIC ACID; PHOSPHATE; RAPAMYCIN; TRANSFERRIN; HEPCIDIN 25, HUMAN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BOLUS INJECTION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFUSION; IRON STORAGE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TIME OF FLIGHT MASS SPECTROMETRY; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA; C-REACTIVE PROTEIN; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; TRANSFERRIN;

EID: 84920093309     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0083-y     Document Type: Article

References (17)

1. Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032
2. Fievet P, Coppin M, Brazier F, Lefevre M, Stephan R, Demontis R (2012) Treatment of iron deficiency in predialysis state by low molecular weight iron dextran high doses intravenously. Nephrol Ther 8:41–46
3. Zager RA, Johnson AC, Hanson SY, Wasse H (2002) Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90–103
4. Sarafidis PA, Rumjon A, MacLaughlin HL, Macdougall IC (2012) Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. Nephrol Dial Transpl 27:50–57
5. Tessitore N, Girelli D, Campostrini N et al (2010) Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transpl 25:3996–4002
6. Gama-Axelsson T, Heimburger O, Stenvinkel P, Barany P, Lindholm B, Qureshi AR (2012) Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol 7:1446–1453
7. Uehata T, Tomosugi N, Shoji T et al (2012) Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transpl 27:1076–1083
8. Zaritsky J, Young B, Wang HJ et al (2009) Hepcidin––a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051–1056
9. Mikhail A, Shrivastava R, Richardson D (2010) Anaemia in CKD. http://www.renal.org/clinical/guidelinessection/AnaemiaInCKD.aspx. Edited by Renal Association 2010. Accessed 12 Sept 2013
10. Ward DG, Roberts K, Stonelake P et al (2008) SELDI–TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci 6:28
11. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF (2010) Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transpl 25:848–853
12. Ashby DR, Gale DP, Busbridge M et al (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976–981
13. Coyne DW, Kapoian T, Suki W et al (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18:975–984
14. Macdougall IC (2013) Ferric carboxymaltose assessment in subjects with iron deficiency anaemia and non-dialysis-dependent CKD (FIND-CKD). http://clinicaltrials.gov/ct2/show/study/NCT00994318. Edited by ClinicalTrials.gov 2013. Accessed 21 June 2013
15. Coyne DW (2011) Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 80:240–244
16. Macdougall IC (2012) New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 59:444–451
17. Ford BA, Eby CS, Scott MG, Coyne DW (2010) Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78:769–773